The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| RXRX | -5.03% | N/A | N/A | -82% |
| S&P | +16.9% | +95.99% | +14.39% | +62% |
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.
It might look like this beaten-down AI-focused company is finally bouncing back, but don't be too quick to pull the trigger.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $19.22M | 33.3% |
| Gross Profit | -$13.24M | -1104.4% |
| Gross Margin | -68.87% | -78.0% |
| Market Cap | $2.06B | 15.5% |
| Net Income | -$171.90M | -76.2% |
| EBITDA | -$152.38M | -64.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $528.22M | 10.9% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $67.59M | -7.6% |
| Short Term Debt | $20.48M | 22.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -62.47% | -10.5% |
| Return On Invested Capital | -43.75% | 5.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$79.57M | 4.6% |
| Operating Free Cash Flow | -$76.42M | 7.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.17 | 3.68 | 2.03 | 2.20 | -51.97% |
| Price to Sales | 28.57 | 38.61 | 35.64 | 32.69 | -10.67% |
| Price to Tangible Book Value | 3.75 | 4.41 | 3.81 | 4.67 | -19.70% |
| Enterprise Value to EBITDA | -16.88 | -10.45 | -10.00 | -10.97 | -29.01% |
| Return on Equity | -78.5% | -61.9% | -86.1% | -86.3% | 21.30% |
| Total Debt | $90.63M | $108.49M | $92.91M | $88.08M | -2.00% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
